Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy.
نویسنده
چکیده
This article updates clinicians on the use of menopausal hormone therapy (HT) by reviewing key recommendations and observations from the North American Menopause Society's (NAMS) 2007 position statement on HT use in peri- and postmenopausal women and then summarizing and interpreting three new reports from the Women's Health Initiative released after the NAMS statement.
منابع مشابه
Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society.
T he termination of the estrogen-progestogen trial of the Women’s Health Initiative (WHI) study in July 2002 was a milestone in the history of postmenopausal hormone therapy. In response, The North American Menopause Society (NAMS) convened an expert Hormone Therapy (HT) Advisory Panel to prepare a report on hormone therapy. After approval from the 2001-2002 NAMS Board of Trustees, the report w...
متن کاملEstrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
OBJECTIVE To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in July 2008 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. METHODS An Advisory Panel of cl...
متن کاملThe North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65.
T he 2012 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) states that hormone therapy (HT) is the most effective treatment for symptoms of menopause. To maximize safety, the initiation of HT should be considered for healthy symptomatic women who are within 10 years of menopause or aged younger than 60 years and who do not have contraindications to use of HT. Co...
متن کاملCardiac autonomic function and vasomotor symptoms: too much break and not enough accelerator?
728 The 2017 hormone therapy position statement of The North American Menopause Society This updated, evidence-based hormone therapy position statement of The North American Menopause Society analyzes the benefi ts and risks of the use of hormone therapy in an individual woman, including age at initiation or time since menopause onset, specifi c formulations or types of hormone therapy, duratio...
متن کاملEstrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.
OBJECTIVE : To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. DESIGN : An Advisory Panel o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cleveland Clinic journal of medicine
دوره 75 Suppl 4 شماره
صفحات -
تاریخ انتشار 2008